Amova Asset Management Americas Inc. Decreases Stake in Cerus Corporation $CERS

Amova Asset Management Americas Inc. cut its position in shares of Cerus Corporation (NASDAQ:CERS) by 6.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,685,177 shares of the biotechnology company’s stock after selling 376,952 shares during the period. Amova Asset Management Americas Inc. owned approximately 2.97% of Cerus worth $9,039,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. AQR Capital Management LLC raised its holdings in shares of Cerus by 291.6% during the 1st quarter. AQR Capital Management LLC now owns 1,429,062 shares of the biotechnology company’s stock worth $1,986,000 after acquiring an additional 1,064,133 shares in the last quarter. Acadian Asset Management LLC increased its position in Cerus by 38.6% in the second quarter. Acadian Asset Management LLC now owns 2,632,304 shares of the biotechnology company’s stock worth $3,710,000 after purchasing an additional 733,683 shares during the last quarter. Qube Research & Technologies Ltd raised its stake in Cerus by 156.5% during the second quarter. Qube Research & Technologies Ltd now owns 749,564 shares of the biotechnology company’s stock valued at $1,057,000 after purchasing an additional 457,347 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in Cerus by 29.3% during the third quarter. Assenagon Asset Management S.A. now owns 1,583,702 shares of the biotechnology company’s stock valued at $2,518,000 after purchasing an additional 358,548 shares in the last quarter. Finally, Millennium Management LLC lifted its position in Cerus by 12.0% during the first quarter. Millennium Management LLC now owns 3,222,327 shares of the biotechnology company’s stock valued at $4,479,000 after purchasing an additional 344,395 shares during the last quarter. Hedge funds and other institutional investors own 78.37% of the company’s stock.

Cerus Price Performance

Shares of NASDAQ CERS opened at $2.24 on Thursday. The firm has a market cap of $430.46 million, a P/E ratio of -28.00 and a beta of 1.51. Cerus Corporation has a 52 week low of $1.12 and a 52 week high of $2.95. The business’s 50 day moving average price is $2.32 and its 200 day moving average price is $1.84. The company has a quick ratio of 1.29, a current ratio of 1.73 and a debt-to-equity ratio of 0.62.

Cerus (NASDAQ:CERS) last announced its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.01) earnings per share for the quarter, meeting the consensus estimate of ($0.01). Cerus had a negative return on equity of 26.09% and a negative net margin of 7.58%.The firm had revenue of $64.58 million during the quarter, compared to analyst estimates of $59.31 million. On average, sell-side analysts expect that Cerus Corporation will post -0.08 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on CERS shares. Wall Street Zen upgraded shares of Cerus from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. TD Cowen reissued a “buy” rating on shares of Cerus in a research note on Monday, January 12th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold”.

Cerus Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.